Skip to main content
Top
Published in: Drugs & Aging 4/2001

01-04-2001 | Therapy in Practice

Botulinum Toxin A Treatment of Adult Upper and Lower Limb Spasticity

Authors: Dr Stefan Hesse, Beate Brandl-Hesse, Anita Bardeleben, Cordula Werner, Michael Funk

Published in: Drugs & Aging | Issue 4/2001

Login to get access

Abstract

This article discusses the treatment of spasticity with botulinum toxin A as a new approach in the neurological rehabilitation of patients after stroke. Clinical studies have been reviewed to provide information about target groups, technical aspects and the advantages and disadvantages of treating spasticity with botulinum toxin A. Open and controlled studies showed that the intramuscular injection of Dysport® 500 to 1500U or Botox® 100 to 300U could reversibly relieve upper limb flexor and lower limb extensor spasticity. A reduced muscle tone, pain relief, better hand hygiene and improved walking function were the main benefits. Patients tolerated the treatment well. Activity or, if not possible, electrical stimulation of the injected muscles may enhance the effectiveness of the costly toxin. Serial casting is another option. With respect to the action of botulinum toxin A, it is suggested that the effect of the toxin could be mediated by paresis of both the extrafusal and intrafusal muscle fibres, thereby altering the afferent discharge in the muscle.
Literature
1.
go back to reference Awad EA, Dykstra D. Treatment of spasticity by neurolysis. In: Kottke FJ, Lehmann JF, editors. Krusen’s handbook of physical medicine and rehabilitation. 4th ed. Philadelphia (PA): WB Saunders, 1990: 1154–62 Awad EA, Dykstra D. Treatment of spasticity by neurolysis. In: Kottke FJ, Lehmann JF, editors. Krusen’s handbook of physical medicine and rehabilitation. 4th ed. Philadelphia (PA): WB Saunders, 1990: 1154–62
2.
go back to reference Das TK, Park DM. Botulinum toxin in treating spasticity. Br J Clin Pharmacol 1989; 43: 401–2 Das TK, Park DM. Botulinum toxin in treating spasticity. Br J Clin Pharmacol 1989; 43: 401–2
4.
5.
go back to reference Bakheit AMO, Ward CD, McLellan DL. Generalised botulismlike syndrome after intramuscular injections of botulinum toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry 1997; 62: 198PubMedCrossRef Bakheit AMO, Ward CD, McLellan DL. Generalised botulismlike syndrome after intramuscular injections of botulinum toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry 1997; 62: 198PubMedCrossRef
6.
go back to reference Schnider P, Berger T, Schmied M, et al. Increased residual urine after local injection of botulinum toxin A [in German]. Nervenarzt 1995; 66: 465–7PubMed Schnider P, Berger T, Schmied M, et al. Increased residual urine after local injection of botulinum toxin A [in German]. Nervenarzt 1995; 66: 465–7PubMed
7.
go back to reference Simpson DM, Alexander DN, O’Brian CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996; 46: 1306–10PubMedCrossRef Simpson DM, Alexander DN, O’Brian CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996; 46: 1306–10PubMedCrossRef
8.
go back to reference Yablon SA, Benjamin TA, Ivanhoe CB, et al. Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: an open-labeled trial. Neurology 1996; 47: 939–44PubMedCrossRef Yablon SA, Benjamin TA, Ivanhoe CB, et al. Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: an open-labeled trial. Neurology 1996; 47: 939–44PubMedCrossRef
9.
go back to reference Pierson SH, Katz DI, Tarsy D. Botulinum toxin A in the treatment of spasticity: functional implications in patient selection. Arch Phys Med Rehabil 1996; 77: 717–21PubMedCrossRef Pierson SH, Katz DI, Tarsy D. Botulinum toxin A in the treatment of spasticity: functional implications in patient selection. Arch Phys Med Rehabil 1996; 77: 717–21PubMedCrossRef
10.
go back to reference Reiter F, Danni M, Ceravolo MG, et al. Disability changes after treatment of upper limb spasticity with botulinum toxin. J Neurol Rehab 1996; 10: 47–52 Reiter F, Danni M, Ceravolo MG, et al. Disability changes after treatment of upper limb spasticity with botulinum toxin. J Neurol Rehab 1996; 10: 47–52
11.
go back to reference Reiter F, Danni M, Lagalla G, et al. Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke. Arch Phys Med Rehabil 1998; 79: 532–5PubMedCrossRef Reiter F, Danni M, Lagalla G, et al. Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke. Arch Phys Med Rehabil 1998; 79: 532–5PubMedCrossRef
12.
go back to reference Palmer DT, Horn LJ, Harmon RL. Botulinum toxin treatment of lumbrical spasticity. Am J Phys Med Rehabil 1998; 77: 349–50CrossRef Palmer DT, Horn LJ, Harmon RL. Botulinum toxin treatment of lumbrical spasticity. Am J Phys Med Rehabil 1998; 77: 349–50CrossRef
13.
go back to reference Hesse S, Lücke D, Malezic M, et al. Botulinum toxin therapy for lower limb extensor spasticity. J Neurol Neurosurg Psychiatry 1994; 57: 1321–5PubMedCrossRef Hesse S, Lücke D, Malezic M, et al. Botulinum toxin therapy for lower limb extensor spasticity. J Neurol Neurosurg Psychiatry 1994; 57: 1321–5PubMedCrossRef
14.
go back to reference Burbaud P, Wiart L, Dubos JL, et al. A randomised, double-blind, placebo-controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996; 61: 265–9PubMedCrossRef Burbaud P, Wiart L, Dubos JL, et al. A randomised, double-blind, placebo-controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996; 61: 265–9PubMedCrossRef
15.
go back to reference Artieda J, Quesada P, Obeso JA. Reciprocal Ia inhibition in spastic hemiplegia. Neurology 1991; 41: 286–9PubMedCrossRef Artieda J, Quesada P, Obeso JA. Reciprocal Ia inhibition in spastic hemiplegia. Neurology 1991; 41: 286–9PubMedCrossRef
16.
go back to reference Rosales RL, Arimura K, Takenaga S, et al. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996; 19: 488–96PubMedCrossRef Rosales RL, Arimura K, Takenaga S, et al. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996; 19: 488–96PubMedCrossRef
17.
go back to reference Hesse S, Krajnik J, Lücke D, et al. Ankle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients: Stroke 1996; 27: 455–60PubMedCrossRef Hesse S, Krajnik J, Lücke D, et al. Ankle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients: Stroke 1996; 27: 455–60PubMedCrossRef
18.
go back to reference Hesse S, Brandl-Hesse B, Seidel U, et al. Lower limb muscle activity in ambulatory children with cerebral palsy before and after the treatment with botulinum toxin A. Restorative Neurol Neurosci 2000; 15: 1–8 Hesse S, Brandl-Hesse B, Seidel U, et al. Lower limb muscle activity in ambulatory children with cerebral palsy before and after the treatment with botulinum toxin A. Restorative Neurol Neurosci 2000; 15: 1–8
19.
go back to reference Hughes R, Walker BC. Influence of nerve-ending activity and of drugs on the rate of paralysis of rat diaphragm preparations by Clostridium botulinum type toxin A. J Physiol 1962; 160: 221–33PubMed Hughes R, Walker BC. Influence of nerve-ending activity and of drugs on the rate of paralysis of rat diaphragm preparations by Clostridium botulinum type toxin A. J Physiol 1962; 160: 221–33PubMed
20.
go back to reference Chen R, Karp BI, Goldstein SR, et al. Effect of muscle activity immediately after botulinum toxin injection for writer’s cramp. Mov Disord 1999; 14: 307–12PubMedCrossRef Chen R, Karp BI, Goldstein SR, et al. Effect of muscle activity immediately after botulinum toxin injection for writer’s cramp. Mov Disord 1999; 14: 307–12PubMedCrossRef
21.
go back to reference Snow BJ, Tsui JKC, Bhatt MH, et al. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990; 28: 512–5PubMedCrossRef Snow BJ, Tsui JKC, Bhatt MH, et al. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990; 28: 512–5PubMedCrossRef
22.
go back to reference Wohlfarth K, Göschel H, Frevert J, et al. Botulinum A toxins: units versus units. Naunyn-Schmiedebergs Arch Pharmcaol 1997; 355: 335–340CrossRef Wohlfarth K, Göschel H, Frevert J, et al. Botulinum A toxins: units versus units. Naunyn-Schmiedebergs Arch Pharmcaol 1997; 355: 335–340CrossRef
23.
go back to reference Childers MK, Stacy DOM, Cooke DL, et al. Comparison of two injection techniques using botulinum toxin in spatic hemiplegia. Am J Phys Med Rehabil 1996; 75: 462–9PubMedCrossRef Childers MK, Stacy DOM, Cooke DL, et al. Comparison of two injection techniques using botulinum toxin in spatic hemiplegia. Am J Phys Med Rehabil 1996; 75: 462–9PubMedCrossRef
Metadata
Title
Botulinum Toxin A Treatment of Adult Upper and Lower Limb Spasticity
Authors
Dr Stefan Hesse
Beate Brandl-Hesse
Anita Bardeleben
Cordula Werner
Michael Funk
Publication date
01-04-2001
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 4/2001
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200118040-00003

Other articles of this Issue 4/2001

Drugs & Aging 4/2001 Go to the issue

Adis Drug Evaluation

Tolterodine

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine